RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) have entered a collaboration to co-develop and commercialize a biosimilar to Merck's (MRK) Keytruda, a blockbuster cancer drug with $29.5 billion in sales in 2024 and 6% year-over-year growth in Q1 2025. RDY and ALVO will share development costs and commercialization rights, with the deal expected to bolster RDY's oncology portfolio, particularly in emerging markets, and expand ALVO's global reach.

Analysis

Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) have entered into a collaboration and license agreement to co-develop and commercialize a biosimilar candidate for Merck’s (MRK) Keytruda, a blockbuster PD-L1 inhibitor that generated $29.5 billion in sales in 2024 and saw its sales grow 6% year-over-year to $7.21 billion in the first quarter of 2025. According to the terms, RDY and ALVO will jointly share all costs for development and manufacturing, with each company retaining the right to commercialize the product globally upon successful development. This strategic move is anticipated to significantly enhance Dr. Reddy’s biosimilar portfolio, particularly in emerging markets, and bolster its capabilities in oncology, a key focus area. For Alvotech, the deal aims to leverage its dedicated R&D and manufacturing platform to expand its biosimilar pipeline into global markets. This collaboration builds upon an existing partnership established in 2024 for AVT03, a biosimilar candidate to Amgen’s Prolia and Xgeva, for which the FDA accepted a regulatory filing for review in March 2025. Year-to-date, Dr. Reddy’s shares have declined 6.5%, which is less severe than the industry’s 11.8% decline, and the company currently holds a Zacks Rank #3 (Hold). The development of such biosimilars is critical for increasing patient access to more affordable treatments for significant diseases like cancer and osteoporosis.

Key Decisions for Investors

• Investors should view the RDY-ALVO collaboration to develop a Keytruda biosimilar as a significant long-term growth opportunity, given Keytruda's substantial market ($29.5 billion in 2024 sales), and closely monitor clinical development and regulatory milestones.
• For Merck (MRK) shareholders, this partnership signals intensifying future competition for its largest revenue-generating drug, necessitating careful evaluation of MRK's strategies to address patent expiration and biosimilar entry.
• The progression of the RDY-ALVO partnership, including the FDA's acceptance of their Amgen biosimilar (AVT03) filing, reinforces their execution capabilities in the biosimilar sector, which could positively influence RDY's current Zacks Rank #3 (Hold) status upon achieving further milestones.
• Consider RDY's relative stock performance, with a 6.5% YTD decline compared to the industry's 11.8% fall, as an indicator of underlying resilience that could be further supported by strategic advancements in high-value biosimilars for oncology and emerging markets.